Literature DB >> 28515260

Multigene Testing for Hereditary Cancer: When, Why, and How.

Kenneth Offit1.   

Abstract

Multigene testing is a complicated area, with advantages and disadvantages of testing for hereditary cancer syndromes. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian and Colorectal provide suggestions for mutation carriers identified by panel tests.
Copyright © 2017 by the National Comprehensive Cancer Network.

Entities:  

Mesh：

Year:  2017        PMID： 28515260     DOI： 10.6004/jnccn.2017.0089

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  5 in total

1.  Testing Positive on a Multigene Panel Does Not Suffice to Determine Disease Risks.

Authors:  Hormuzd A Katki; Mark H Greene; Maria Isabel Achatz
Journal:  J Natl Cancer Inst       Date:  2018-08-01       Impact factor: 13.506

2.  A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.

Authors:  Ana F Best; Margaret A Tucker; Megan N Frone; Mark H Greene; June A Peters; Hormuzd A Katki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-28       Impact factor: 4.254

3.  Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.

Authors:  Carlos H Barcenas; Maryam N Shafaee; Arup K Sinha; Akshara Raghavendra; Babita Saigal; Rashmi K Murthy; Ashley H Woodson; Banu Arun
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

4.  BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.

Authors:  Melissa S Cline; Rachel G Liao; Michael T Parsons; Benedict Paten; Faisal Alquaddoomi; Antonis Antoniou; Samantha Baxter; Larry Brody; Robert Cook-Deegan; Amy Coffin; Fergus J Couch; Brian Craft; Robert Currie; Chloe C Dlott; Lena Dolman; Johan T den Dunnen; Stephanie O M Dyke; Susan M Domchek; Douglas Easton; Zachary Fischmann; William D Foulkes; Judy Garber; David Goldgar; Mary J Goldman; Peter Goodhand; Steven Harrison; David Haussler; Kazuto Kato; Bartha Knoppers; Charles Markello; Robert Nussbaum; Kenneth Offit; Sharon E Plon; Jem Rashbass; Heidi L Rehm; Mark Robson; Wendy S Rubinstein; Dominique Stoppa-Lyonnet; Sean Tavtigian; Adrian Thorogood; Can Zhang; Marc Zimmermann; John Burn; Stephen Chanock; Gunnar Rätsch; Amanda B Spurdle
Journal:  PLoS Genet       Date:  2018-12-26       Impact factor: 5.917

5.  Toward automation of germline variant curation in clinical cancer genetics.

Authors:  Vignesh Ravichandran; Zarina Shameer; Yelena Kemel; Michael Walsh; Karen Cadoo; Steven Lipkin; Diana Mandelker; Liying Zhang; Zsofia Stadler; Mark Robson; Kenneth Offit; Joseph Vijai
Journal:  Genet Med       Date:  2019-02-21       Impact factor: 8.822
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.